biostudies-literatureRomano AAssociazione Italiana per la Ricerca sul Cancro8735-8746https://www.ebi.ac.uk/biostudies/studies/S-EPMC7724487biostudies-literatureUnknown9(23)<h4>Background</h4>The neutrophil to lymphocyte ratio (NLR) and the lymphocyte to monocyte ratio (LMR) can reflect both the myeloid dysfunction and T-cell immune suppression and have prognostic significance.<h4>Methods</h4>In 771 newly diagnosed advanced-stage Hodgkin Lymphoma (HL) patients we evaluated the baseline values of NLR and LMR as predictors of clinical outcome. According to the multicenter prospective phase II GITIL-HD0607 trial, all patients received two ABVD courses and if PET-2 negative received four additional ABVD cycles while if PET-2-positive patients were randomized to either BEACOPP escalated (Be) plus BEACOPP baseline (Bb) (4 + 4 courses) or Be + Bb (4 + 4) and Rituximab. PET scans were centrally reviewed by an expert panel by Blinded Independent Central Review.<h4>ResCancer medicineThe neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.PMC7724487IG2013Biggi AZanotti RTrentin LGini GGallamini APatti CCorradini PSchiavotto CCantonetti MTarella CPicardi MGavarotti PBolis SViero PMassimo Gianni ACimminiello MChauvie SRossi ADi Raimondo FLa Nasa GViviani SZoli VRambaldi ARomano APavoni CParvis GFerreri AJMfalseThe neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.<h4>Background</h4>The neutrophil to lymphocyte ratio (NLR) and the lymphocyte to monocyte ratio (LMR) can reflect both the myeloid dysfunction and T-cell immune suppression and have prognostic significance.<h4>Methods</h4>In 771 newly diagnosed advanced-stage Hodgkin Lymphoma (HL) patients we evaluated the baseline values of NLR and LMR as predictors of clinical outcome. According to the multicenter prospective phase II GITIL-HD0607 trial, all patients received two ABVD courses and if PET-2 negative received four additional ABVD cycles while if PET-2-positive patients were randomized to either BEACOPP escalated (Be) plus BEACOPP baseline (Bb) (4 + 4 courses) or Be + Bb (4 + 4) and Rituximab. PET scans were centrally reviewed by an expert panel by Blinded Independent Central Review.<h4>Res2020-01-01T00:00:00Z2020 Dec2026-05-03T05:05:33.607Z2021-02-20T10:55:05ZS-EPMC77244873315575410.1002/cam4.3396